Metibasol (Thiamazole)

Thiamazole blocks the enzyme thyroid peroxidase, which is essential for adding iodine to tyrosine residues and coupling them to form thyroxine (T4) and triiodothyronine (T3). By inhibiting this step, the drug reduces the synthesis of active thyroid hormones and mitigates the hyperactive thyroid state.

The appropriate dose of Metibasol is individualized by a qualified prescriber based on the severity of the thyroid condition, patient age, weight, and response to therapy. Dosage regimens can vary, and any adjustments should be made under medical supervision.

Safety data for thiamazole in pregnancy and lactation are limited. Use during pregnancy is generally reserved for situations where the benefits outweigh potential risks, and it should be avoided in the first trimester if possible. Breastfeeding mothers should consult their physician before using Metibasol.

To request Metibasol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to thiamazole is propylthiouracil (PTU). Both inhibit thyroid hormone synthesis, but PTU also blocks peripheral conversion of T4 to T3. Thiamazole is generally preferred for long‑term management because of a more favorable safety profile, whereas PTU is reserved for specific situations such as the first trimester of pregnancy.

Metibasol tablets should be stored at room temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Metibasol is taken orally, usually with a glass of water. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal discomfort. Patients should follow the prescriber’s instructions regarding timing and whether the dose should be split throughout the day.

The most critical adverse events include agranulocytosis, a severe drop in white blood cells that can lead to infection, and serious liver injury such as hepatitis. Patients should promptly report fever, sore throat, jaundice, dark urine, or unexplained fatigue to their healthcare provider.

Metibasol is contraindicated in individuals with known hypersensitivity to thiamazole or any thioamide compounds. It should be used with caution, or avoided, in patients with severe liver disease, existing bone marrow suppression, or those who are pregnant during the first trimester unless no safer alternative exists.